Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study. // Blood Immunology & Cellular Therapy. – URL: https://www.sciencedirect.com/science/article/pii/S305059762600031X?dgcid=rss_sd_all
Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study. Blood Immunology & Cellular Therapy. https://www.sciencedirect.com/science/article/pii/S305059762600031X?dgcid=rss_sd_all
“Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study.” Blood Immunology & Cellular Therapy.
@article{article38454,
title = {Real-world outcomes of tafasitamab-lenalidomide in patients with transplant-ineligible R/R DLBCL from the PRO-MIND study},
journal = {Blood Immunology \& Cellular Therapy},
url = {https://www.sciencedirect.com/science/article/pii/S305059762600031X?dgcid=rss_sd_all}
}